Ractigen doses first subject in Phase I ALS treatment trial
Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA)…
News
XBiotech halts all rheumatology research after missing Phase II endpoints
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
Zura Bio initiates Phase II systemic sclerosis treatment trial
First patient dosed as Marengo’s invikafusp alfa trial expands to Europe
BMS sees success in Phase III Sotyktu psoriatic arthritis trials
JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
GSK’s combo therapy trial for advanced ovarian cancer meets primary endpoint
